Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MCM6 Double Nickase Plasmid (h): sc-402146-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MCM6 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- MCM6 Double Nickase Plasmid (h) and MCM6 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting MCM6. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MCM6 Antibody (H-8): sc-393618
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MCM6 Double Nickase Plasmid (h) | sc-402146-NIC | 20 µg | $410.00 | |||
MCM6 Double Nickase Plasmid (h2) | sc-402146-NIC-2 | 20 µg | $410.00 |
MCM6 encodes a core subunit of the MCM2–7 helicase complex that licenses DNA replication origins and drives replication fork progression during S phase. Through regulated loading onto chromatin with ORC, CDC6, and CDT1, MCM6 supports genome duplication, replication stress responses, and coordination with checkpoint pathways such as ATR/CHK1. Dysregulated MCM6 expression or activity is frequently used as a marker of proliferative capacity and has been associated with genomic instability phenotypes observed in diverse cancers and other hyperproliferative states. Perturbing MCM6 provides a direct route to study origin licensing, fork stability, and cell-cycle control in human cells.
MCM6 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the MCM6 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within MCM6. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt MCM6 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of MCM6-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.